Beam Therapeutics Inc.
BEAM
$15.12
-$1.34-8.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.07M | 14.27M | 11.77M | 7.41M | 316.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.07M | 14.27M | 11.77M | 7.41M | 316.19M |
| Cost of Revenue | 101.44M | 94.26M | 87.04M | 84.82M | 140.08M |
| Gross Profit | -71.38M | -79.99M | -75.27M | -77.41M | 176.12M |
| SG&A Expenses | 28.66M | 26.52M | 29.63M | 26.72M | 43.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 130.10M | 120.77M | 116.67M | 111.54M | 183.33M |
| Operating Income | -100.04M | -106.50M | -104.90M | -104.13M | 132.86M |
| Income Before Tax | -90.35M | -96.67M | -91.01M | -98.67M | 144.16M |
| Income Tax Expenses | 0.00 | -- | 39.00K | -- | 1.37M |
| Earnings from Continuing Operations | -90.35M | -96.67M | -91.05M | -98.67M | 142.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.35M | -96.67M | -91.05M | -98.67M | 142.80M |
| EBIT | -100.04M | -106.50M | -104.90M | -104.13M | 132.86M |
| EBITDA | -94.59M | -101.03M | -99.32M | -98.70M | 138.22M |
| EPS Basic | -1.09 | -1.17 | -1.11 | -1.21 | 1.77 |
| Normalized Basic EPS | -0.67 | -0.72 | -0.65 | -0.73 | 1.11 |
| EPS Diluted | -1.09 | -1.17 | -1.11 | -1.21 | 1.72 |
| Normalized Diluted EPS | -0.67 | -0.72 | -0.65 | -0.73 | 1.08 |
| Average Basic Shares Outstanding | 82.82M | 82.41M | 82.31M | 81.70M | 80.86M |
| Average Diluted Shares Outstanding | 82.82M | 82.41M | 82.31M | 81.70M | 82.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
